Aisimai
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Aisimai - overview
Established
2016
Location
Guangzhou, Guangdong, China
Primary Industry
Biotechnology
About
Established in 2016 and based in Guangzhou, China, Aisimai is a biomedical developer that focuses on bispecific antibody drugs. Dr. Wenjun Zhang, the CEO of the company, once served as the R&D staff of Novartis and MacroGenics. More than 20% of the core research team has master's degree.
The company cooperates with Zhenge Biotech, OPM and Joinn. The company provides dual-targeted antibody drugs for tumor treatment field, such as gastric cancer, breast cancer and rheumatoid arthritis. The product of the company includes EX103 and EX101. The company adopts antibody discovery and verification platform and bispecific antibody platform ExMab®, including antibody engineering construction and screening and clinical medication.
The company will increase the investment of developing new products and declare investigational new drug(IND).
Current Investors
Oriza Holdings, YuanBio Venture, CAS Investment Management
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.excelmab.com
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Aisimai - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chief Executive Officer & General Manager | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.